^
    Back
    Association details:
    Biomarker:IL6 elevation
    Cancer:Hepatocellular Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    JHEP Rep
    Title:

    High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

    Published date:
    01/16/2023
    Excerpt:
    ...participants with high baseline IL-6 levels had a reduced response rate and worse progression-free and overall survival after Ate/Bev treatment compared with those with low baseline IL-6 levels.
    DOI:
    10.1016/j.jhepr.2023.100672
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

    Published date:
    02/10/2022
    Excerpt:
    We performed simultaneous measurement of 34 proteins using a multiplex bead-based immunoassay in baseline plasma from 34 patients who underwent Atezo/Bev therapy as first- or second-line treatment….The progression-free survival (PFS) and overall survival (OS) of patients with high IL-6 levels were significantly shorter than those of patients with low IL-6 levels.
    DOI:
    10.3390/cancers14040883